Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the ...
Moleculin Biotech, Inc. is a clinical stage pha...
Citizen Health is a public benefit company rebuilding healthcare on an open & tran...
Citizen Health is a public benefit company rebu...
Aviana Molecular Technologies, LLC (Aviana) is an Orlando, FL based point of care ...
Aviana Molecular Technologies, LLC (Aviana) is ...
CVBM Interests has designed a social media mobile app called Heart Rate Social. Th...
CVBM Interests has designed a social media mobi...
The objective of Phenomix Sciences, LLC (Phenomix) is to provide healthcare soluti...
The objective of Phenomix Sciences, LLC (Phenom...
SelenBio, Inc is a biotechnology company specializing in the prevention of bacteri...
SelenBio, Inc is a biotechnology company specia...
We are a clinical stage biopharmaceutical company leveraging our two proprietary t...
We are a clinical stage biopharmaceutical compa...
Join the National Investor Network and get the latest information with your interests in mind.